E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
Alzheimer's disease is a brain disorder that slowly destroys memory and thinking skills, and, eventually, the ability to carry out the simplest tasks. |
|
E.1.1.2 | Therapeutic area | Psychiatry and Psychology [F] - Mental Disorders [F03] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10001896 |
E.1.2 | Term | Alzheimer's disease |
E.1.2 | System Organ Class | 100000004852 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The main objective of the present trial is: • to evaluate the effect of TW001 on oxidative stress biomarkers • to evaluate the safety of TW001 in patients with Alzheimer’s Disease
|
|
E.2.2 | Secondary objectives of the trial |
The secondary objective of the present trial is: • to evaluate the pharmacokinetics of TW001 in patients with Alzheimer’s Disease. Exploratory objectives of the present trial are: - to explore the early effect of TW001 on the CDR-SB and the Cognitive Functional Composite (CFC) endpoint as a clinical outcome measur - to explore the early effect of TW001 on a variety of individual biomarkers to define a composite biomarker to be used in a follow-up, long-term clinical study to predict disease progression
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
To be eligible for participation in this trial, a patient must meet the following criteria: [1] Age 55 – 80 years (both inclusive), male or female. [2] Body mass index between 18.5 to 30.0 kg/m2 (both inclusive). [3] Should meet the criteria for early clinical stage AD according to the NIA-AA criteria research framework: a. Gradual and progressive change in memory function reported by patient or informant over more than 6 months, b. Clinical syndrome of MCI due to AD or mild AD dementia, c. An MMSE score ≥ 20 at screening, d. Biomarker classification A+T+N+ or A+T+N- based upon: I. CSF profile consistent with AD (an Aβ42 concentration of <1000 pg/mL AND phosphorylated tau (p-Tau) >19 pg/mL, or a ratio of p-tau/Aβ42 of ≥0.020) taken during the screening period prior to the day of the first dose of study medication or, II. Documented evidence of a CSF profile consistent with AD obtained within the previous 12 months, or III. Documented amyloid positron emission tomography (PET) scan evidence acquired within the previous 12 months. [4] A reliable and competent trial partner/caregiver who can assist and witness dosing and is willing to accompany the patient to all visits. The trial partner/caregiver should understand the nature of the trial and adhere to trial requirements (e.g., visit schedules, evaluations) and confirm this by co-signing the informed consent of the patient or signing of a separate informed consent of the partner/caregiver according to the local requirements. [5] If a patient is taking medication, supplements or vitamins, the dose must be stable for at least the last 3 months before screening, and the patient must be willing to remain on the same dose for the duration of the trial. [6] A male patient abstains from sexual intercourse, or is vasectomized (> 6 months), or will use a condom with spermicide during sexual intercourse during the trial and for three months after participation in the trial and will abstain from sperm donation during the trial and for three months after participation in the trial. [7] A female patient should not be of reproductive potential: A female patient who is not of reproductive potential is defined as one who: (a) Has reached natural menopause (defined as 6 months of spontaneous amenorrhea with serum follicle-stimulating hormone [FSH] levels in the postmenopausal range as determined by the local laboratory, or 12 months of spontaneous amenorrhea); (b) Is 6 weeks post-surgical bilateral oophorectomy with or without hysterectomy; or (c) Has undergone bilateral tubal ligation. Spontaneous amenorrhea does not include cases for which there is an underlying disease that causes amenorrhea (e.g., anorexia nervosa). [8] Capable of providing informed consent and complying with trial procedures. |
|
E.4 | Principal exclusion criteria |
Patients presenting at screening visit that meet any of the following criteria will not be included in the trial: [1] A known history of stroke that is clinically important in the investigator’s opinion. [2] Evidence of a clinically relevant neurological disorder other than AD at screening, including but not limited to: vascular dementia, Parkinson’s disease, frontotemporal dementia, Huntington’s disease, amyotrophic lateral sclerosis, multiple sclerosis, progressive supranuclear palsy, dementia with Lewy bodies, other types of dementia, neurosyphilis or head trauma with loss of consciousness that led to persistent cognitive deficits. [3] A history of seizures or epilepsy within the last 5 years before screening. [4] Evidence of a clinically relevant or unstable psychiatric disorder, based on DSM-5TM criteria, including schizophrenia or other psychotic disorder, bipolar disorder, major depression, or delirium. Major depression in remission is not exclusionary. [5] Renal impairment as indicated by a creatinine clearance of less than 50 mL/min as calculated by the Cockcroft Gault equation78. [6] Patient has a history of any of the following conditions: a. Clinically significant hepatic disease, b. AST or ALT levels of ≥ 2 times upper limit of normal (ULN), c. Biliary tract disease, d. Patient has a positive screening test for HIV, hepatitis B or C. [7] Presence of any of the following clinical conditions: a. Unstable cardiac, pulmonary, endocrine, hematologic or active infectious disease, b. Unstable psychiatric illness defined as psychosis, untreated major depression within 90 days of the screening visit, c. A history of cancer within 3 years prior to screening, except adequately treated squamous or basal cell carcinoma of the skin or carcinoma in situ of the cervix that has been successfully treated. [8] History or signs/symptoms of lumbar spine/disc disease including but not limited to scoliosis, herniation, or any other contraindication to lumbar puncture. [9] History of known sensitivity or intolerability to edaravone, related substances of edavarone, or to any of the excipients. [10] Use of OAT-3 inhibitors such as probenecid, cimetidine, and diclofenac. [11] Current substance abuse or alcohol dependence. [12] Exposure to any investigational drug within 30 days of the screening visit. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Pharmacodynamics Evaluate the effect of TW001 on oxidative stress biomarkers, including: - 8-hydroxy-2’-deoxyguanosine (8-OHdG) / 8-hydroxyguanosine (8-OHG) in plasma and CSF - 3-nitrotyrosine (3-NT) in plasma and CSF - Uric acid in plasma Safety - Nature, frequency and severity of adverse events - Values and changes from baseline in vital signs and 12-lead electrocardiogram (ECG) - Values and changes from baseline in safety laboratory tests (hematology, biochemistry, coagulation, urinalysis) - Changes in physical and neurological examinations - Changes in Electroencephalogram (EEG) |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
After completion of the clinical part of the trial and database closure. |
|
E.5.2 | Secondary end point(s) |
Pharmacokinetics The following plasma PK parameters will be obtained for plasma edaravone after orally administered TW001: - AUC(0-t), Cmax and tmax of edaravone Exploratory Endpoints Explore the effect of TW001 on surrogate markers of AD pathogenesis and progression, such as: - Amyloid β (Aβ) 42-residue (Aβ42) in plasma and CSF - Amyloid β (Aβ) 40-residue (Aβ40) in plasma and CSF - Phosphorylated tau epitopes in plasma and CSF - Total tau (t-tau) in CSF - Glial Fibrillary acidic protein (GFAP) in plasma and CSF - Chitinase-3-like protein 1 (YKL-40) in CSF - Neurofilament light (NFL) in plasma and CSF - Neurogranin (NRGN) in CSF Explore the effect of TW001 on oxidative stress biomarkers, including: - 8-hydroxy-2’-deoxyguanosine (8-OHdG) / 8-hydroxyguanosine (8-OHG) in urine - 3-nitrotyrosine (3-NT) in urine Explore the early effect of TW001 on: - Cognitive functioning using the CDR-SB and the CFC - Neuronal activity and connectivity through EEG |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
After completion of the clinical part of the trial and database closure. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 2 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 5 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
LVLS. Follow-up visit (not earlier than 14 days after the last dosing) |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | 9 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial months | 9 |